New York, NY / June 4, 2014 / Market Exclusive announces that Aegis Capital Corp has reiterated a Buy rating and 12-month price target of $21.00 on NeoStem, Inc. .
http://ift.tt/1l82HuB
http://ift.tt/1l82HuB
Stem Cell Research News: News on Stem Cell Research continually updated from thousands of sources around from the B Media Network.
No comments:
Post a Comment